Hoppa till innehållet

Redeye: Hansa Biopharma - Improved sales prospects

Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and supporting pipeline progress over the next 12 months. Many countries supported the European launch, and the Eurotransplant program was initiated. Our Base Case is SEK110 (100) with a Bull Case of SEK210 (210) and a Bear Case of SEK15 (15).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera